Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7474242 | 0.98 | MAPT (0.43) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL13815383 | 0.83 | MAPT (0.47) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL29375628 | 0.80 | CYP3A4 (0.42) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL10139683 | 0.80 | CYP3A4 (0.42) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL94021 | 0.80 | CYP3A4 (0.42) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL275010 | 0.78 | MAPT (0.71) | MAPTALDH1A1EGFRERBB2TSHR | |
| SCHEMBL1498625 | 0.77 | TSHR (0.45) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL10993752 | 0.76 | RAB9A (0.44) | MAPTCYP3A4RECQLALDH1A1EGFR | |
| SCHEMBL3664908 | 0.76 | TSHR (0.47) | MAPTCYP3A4CASP1RECQLALDH1A1 | |
| SCHEMBL11805111 | 0.76 | ALDH1A1 (0.39) | MAPTCYP3A4CASP1RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891191-A1 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1999-01-20 | — | — | EP | claimed |
| WO-1997036616-A2 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-10-09 | — | — | WO | claimed |
| CN-103626776-B | Pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, preparation methods of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, and application of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives in oncotherapy | 北京师范大学 | 2017-02-15 | — | — | CN | disclosed |
| CN-103193722-B | Novel quinazoline quinoline nitrogen mustards compound and preparation method thereof and cancer therapeutic applications | BEIJING NORMAL UNIVERSITY (CN) | 2016-02-24 | — | — | CN | disclosed |
| CN-103626776-A | Pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, preparation methods of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, and application of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives in oncotherapy | UNIV BEIJING NORMAL | 2014-03-12 | — | — | CN | disclosed |
| US-20130072447-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGANOSTIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-21 | — | — | US | disclosed |
| US-20110087004-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS | RAMANATHAN SRINIVASAN | 2011-04-14 | — | — | US | disclosed |
| US-7740882-B2 | polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability | RAMANATHAN SRINIVASAN | 2010-06-22 | — | — | US | disclosed |
| US-20060029667-A1 | polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability | RAMANATHAN SRINIVASAN | 2006-02-09 | — | — | US | disclosed |
| US-20030091640-A1 | Bioavailability | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-05-15 | — | — | US | disclosed |
| WO-2002062396-A2 | ENHANCED ORAL AND TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS USING POLYMER CONJUGATES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0891191-A1 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036616-A2 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-10-09 | — | — | WO | disclosed |
| EP-0711768-A1 | BENZIMIDAZOLE DERIVATIVE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-15 | — | — | EP | disclosed |